{"name":"Menarini Group","slug":"menarini","ticker":"Private","exchange":"Private","domain":"menarini.com","description":"Menarini Group is a private Italian pharmaceutical company with a focus on cardiovascular, respiratory, and oncology therapies. The company has a significant presence in the global market with a portfolio of established brands and a pipeline of innovative products. Menarini Group operates in over 100 countries and has a strong commitment to research and development. The company's key products include Brilinta, Resclo, and Menveo.","hq":"Florence, Italy","founded":0,"employees":"","ceo":"Elcin Barker Ergun","sector":"Big Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":4500000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Brilinta patent cliff ($1.5B at risk)","drug":"Brilinta","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Resclo patent cliff ($500M at risk)","drug":"Resclo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Menarini Group Reports Strong Earnings Growth in 2022","summary":"Menarini Group reported a 15% increase in revenue and a 20% increase in net income for the year 2022.","drugName":"","sentiment":"positive"},{"date":"2022-06-01","type":"deal","headline":"Menarini Group Acquires Majority Stake in Italian Biotech Firm","summary":"Menarini Group acquired a majority stake in Italian biotech firm, Biotech Italia, to expand its presence in the Italian market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPYW9BLWZ4aUw4eHNFeXZ3cWhhMmp4SF9MVkhDcUdJZjdLWXhPczBMMXVaMnZNMm53MTI5bWxXWlpSVG1HRlVPN1dIWGdfaTJyNWNZcVRNOThJaFIwVVk4Tl9hTThCZWE5UFExUlJrbnd5R3NTUFBuSGdtdUJfTUV1XzMwN0hCSkx2Sk9ja2JwaXE1ek9DcDZ3ZDZiSG5LOXpUa19hWHpXYm9jajd0ZjdmZVJ5LVZCM3QtRldncXB1VlFQNk14MVdQLVpoelU0SGNqcGczdUV4QXJNNHVvTjlKaUNuT2JRM0NxU2hZMHFHaGRaWDBxa2YtUQ?oc=5","date":"2026-03-09","type":"pipeline","source":"GlobeNewswire","summary":"Menarini nears €4.9 billion in 2025 and focuses on talent and AI as ‘giant’ players enter pharma - GlobeNewswire","headline":"Menarini nears €4.9 billion in 2025 and focuses on talent and AI as ‘giant’ players enter pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNa3BtMmp3WWpMR3NSb1V5aHp3LTBhTlNKMXdlMG5RM3ZCOXZCOFpxc213bVRfRWdYNmFMc2JJSjJWVDMxWmRIUVdlSWROdFhLWnppX056djdXUkZubXlKaC1wNjVFSUxkV2xlVmFlUlJELVFZTTFzVHEzWU9ReEhfTzc3OGlXcWRMTV9zbXR5c2RPbHN5OWU5U0hpdXBZY1lJREljS1RzTUxjUUIzYkJRQUdvOVVSSGdSdXJtX0RmVXJQNTBJNGdqclhIQXZEUl96VDBJNUNnTWdQRmE5czVMeEI2WlJhdDB4OUZBaHNBeThvMXBUdlZTSFEtQU1DQWhLNE0tZndfSTZaZmc1NFlLN0Q3UGVIZDI4cUJ0M3FnZWZJbUh5TVRnbE9YQmU2NHBkdGV1aEN1NDBfVXFoWHVhMG82ckZJY29E?oc=5","date":"2025-12-08","type":"trial","source":"Newswire Canada","summary":"Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium - Newswire Canada","headline":"Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Ca","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-09-02","type":"regulatory","source":"PR Newswire","summary":"Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercho","headline":"Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNcW14aWNlUC04ZGpLOGdoNHUxZ0hKSnRPeE9yb0xTY2xpZWE0aFpsdi1yUXlkUmZCSXZ4Sjg2N2RNTTZqc09RUG82RFlTZzdMQjk0Z3FNM1UyQV9UWkxROHNTdzZhNll0emJMa1k0a2lCTmg3LTN5SXZkT201VUJFZHRFWk16ZFFReE1SYnZYY2w4LU9DTUE?oc=5","date":"2025-03-13","type":"pipeline","source":"MobiHealthNews","summary":"Insilico Medicine scores $110M for AI-enabled drug discovery - MobiHealthNews","headline":"Insilico Medicine scores $110M for AI-enabled drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxPS3dHb0trcmdmNnp2M0hBSUhwWDFtRGZPZHk3NGdYRGxLUUpTTm1iZDQydGd5VlA5MEprR3ZVaDBVTU5IRlpoeEFsY0FVMGluTVpNekFteXFXWXB5YV94aFhWb2pfeUZ6UnlNQXd5bDl6M2RheHBoejlfUUJDVHdmQ0hHRl8tMU9sX1lIX1VGV3hRVDBHREUtdlpCR0pIUXZmX1hjSEpLRFFlTlNmYzF6dEpIU3ZXaW1xaWJVWnJvaHJCNlByRmtFSWY3V3pqMmZ5RTBzYWFBSE1DRi1ZV1FMc1J4T3hCZWc3a3VaWWJCNVRWRk4yNXFBZmNJNUV4a1AzNEo3S0MxZDMtV2drYndKLWJ1bGt2ejZlZUxZSnNJaDNHcXBEUEl0SzVvcTI3OXZnZ201QnB2LXNTRzZVMWZhSVE0UDVVSWhKVmRDM29LRl8wVXFrN2pzVkZhOTFlVlNPV2s0QQ?oc=5","date":"2024-12-16","type":"trial","source":"PR Newswire","summary":"Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg - PR Newswi","headline":"Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetr","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOaUpBTHdMREVScWZuTV9ZT2tZRGhfMFU4TS1HYnR5ZG82YW00Y1FtRnozMlhvQ1hmQWRSaXprSGJyYXJRVDR1eXJ3X3JpcEhDM1hyQ3ZFdDh1eFBlVnI4UFBIcG9aa2xmMWo0REIyWHNuRExjb1hMZnVDYVVfWU4tSHBYZlJ5QjdYdDJn?oc=5","date":"2023-09-22","type":"deal","source":"lupin.com","summary":"Lupin Acquires Five Brands from Menarini - Lupin | Press Release - lupin.com","headline":"Lupin Acquires Five Brands from Menarini - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-02-21","type":"regulatory","source":"Karyopharm","summary":"Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethas","headline":"Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNRUM2SzlaNE9XRWFMbFVpbTNfY1E5NkxnSFlWQl9EelYzbFBZeTByaDZmOURtNy10ZzBneWZ0Sk1EREV0U2hkLWg0UWRQVF9LaTFabWgwd2psdndmMmJBcm9WZVFCREo3YlZaZHdpbVhUenEtendzVWVkc1EwaU4wRzVMbjlraFluRU1wbVlNd0xLXzFNSFE?oc=5","date":"2023-01-30","type":"regulatory","source":"BioPharma Dive","summary":"FDA approves cancer drugs from Lilly, Menarini - BioPharma Dive","headline":"FDA approves cancer drugs from Lilly, Menarini","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPVEtJV21WNlNyYkNxWk56dS1JaHRUTkd6S0xHZzRUSThqTzZHUmRwVUszYTJwdWVDRVU4R05oLUxJSGo4TTk4ZUZsY0hkZkZIczNNaXY0bDZpVWRfRDBMcWpselFmOEZTNERocF91S2RGR1NJQndOMnExbXVwTlg2bnN5N19DQ0p0cHJZTEtkcHBqNE5XbzhXVzRkUXAybTB0Smw0dkpqOUVaZ3RkWWI5d3B1RnZMN2xmTzJXd0FhT2F0WlpWOFNWLU9nYnNVMlZIdmlpLXBweUZpU2NtTWIzcmFhbGUwSi05aE1SRXF2YjdZNnhGckRaUjJ4R2JmbWFyeTMwQ3RMNXBQN1BJaTdBYS0taXlzckJtYnRxc0xBYmNNTjA?oc=5","date":"2022-10-31","type":"pipeline","source":"Karyopharm","summary":"Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis - Karyopharm","headline":"Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor f","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZ3VpdE50NWhOYXVhM3J1VGxXYlJxcXNTZFpXT1NtTU1OempfUlZjNUNPdVNYaFZ1Y25lWmJsbkQxSXRBdHRyaDF1aG9LTmY5OFpLellCTVVtQ0xCSHB1cGRkYzRoeFY1MWN5V3dWTlh1RWhnb0RVeDRpa09EMDdhUFNYWkFBVkttRXRLZWtMMHUyUmtQbkZKSUczMFFSSWltam4weA?oc=5","date":"2022-07-26","type":"pipeline","source":"williamblair.com","summary":"NewAmsterdam Pharma and Frazier Lifesciences Acquisition Transaction - williamblair.com","headline":"NewAmsterdam Pharma and Frazier Lifesciences Acquisition Transaction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQM1Fod1JmNVhvNTh1NTJmSGtlOVZqaTh4M1hPbHFXYnI0ZUt5NkFMZ0NTa0RGTmhHdGwtNHItRHluOXRyYnBTNzduRno2a2ZEZ3dBczlqSmthZW5wVGxHVHFkM094MVg1TTBPZExSaHdzV2Zpa0NMZEhiV09NNWJ0OXIxMzRtUUxuZm5TNlRkMTJFYzBkQ0FneEtMYXVmRTE4Z3QwSGpvQlpoRVA2VnFUNFljb3JpOHRCMWVkb3VkWk9mQUVySG0xM3JBb3puYUxfekRQNkwxZ044eTZKbDJqSTBTUjRYeGxPMHd5NXRR?oc=5","date":"2022-06-28","type":"deal","source":"PR Newswire","summary":"NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe - PR Newswire","headline":"NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOWHdqX19vOXNxa3pVODZTajUyUF9oZlh3Tk1YRGJTTGdYb1RIekV6bzBNZVl3TW1pOE4zNUlwbUMzY3VuZUI2X21YLU9adDFlTUJsNUNOZHdKamZxeU1BTFJJT21xVlF6cUc1c1JfY2VwNkdMb2JVRUF0LUVfU1FWaEVIRkJDYV9OWlFR?oc=5","date":"2020-05-05","type":"deal","source":"Pharmaceutical Technology","summary":"Menarini Group to buy Stemline Therapeutics in deal valued at $677m - Pharmaceutical Technology","headline":"Menarini Group to buy Stemline Therapeutics in deal valued at $677m","sentiment":"neutral"}],"patents":[{"drugName":"Resclo","drugSlug":"salmeterol","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"EU","annualRevenue":500000000},{"drugName":"Brilinta","drugSlug":"ticagrelor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novartis","Pfizer","AstraZeneca"],"therapeuticFocus":["Cardiovascular","Respiratory","Oncology"],"financials":null,"yahoo":null}